Pharmacokinetics and palatability of a 50 mg obefazimod minitablet versus the adult capsule

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, open-label, two-part Phase 1 study enrolls healthy adult volunteers to compare the pharmacokinetics and palatability of a 50 mg obefazimod minitablet with the marketed 50 mg capsule. Part 1 will administer single doses to determine a minitablet dose that produces systemic exposures (Cmax and AUC) comparable to the adult capsule. Part 2 will examine the 50 mg minitablet taken with water or mixed into soft foods (applesauce, yogurt, or chocolate pudding) to evaluate relative bioavailability versus the capsule taken without a vehicle. Formulation development was guided by in vitro dissolution testing and physiologically based biopharmaceutics modeling to match adult capsule exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 55 years inclusive at the time of signing informed consent
* Must agree to adhere to the contraception requirements.
* Healthy male or non-pregnant, non-lactating female participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead ECG and laboratory safety tests without any clinically significant abnormalities
* Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
* Weight ≥50 kg at screening Inclusion criteria.

Exclusion Criteria:

* Presence or history of clinically significant allergy requiring treatment, as judged by the investigator.
* History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator
* Participants with a history of cholecystectomy or gall stones
* Participants with chronic or recurrent infection
* Participants who have tested positive for tuberculosis
* Participants with a history of shingles within the last two months
* History of opportunistic infection while not on immunosuppressive therapy
* Part 2 only: Participant has a medical condition that may adversely affect taste or smell activity including but not limited to mouth ulcers, significant gum disease, and respiratory and/or sinus infection or cold
* Part 2 only: Participant does not agree to the consumption of, or has any known allergies to any of the food vehicles used in this study (applesauce, chocolate pudding, yogurt)
* Participants who have received any IMP (Investigational Medicinal Product) in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
* Participants who have previously been administered IMP in this study
* Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
* Participants who are taking, or have taken, any prescribed or over-the-counter drug, hormone replacement therapy (HRT) or herbal remedies (other than up to 4 g of paracetamol per day and hormonal contraception) in the 14 days or 5 elimination half-lives, whichever is longer, before first IMP administration (see Section 11.4). Exceptions may apply, as determined by the investigator
* Having any vaccination or planned vaccination within 28 days before Day 1. Participants who received live vaccine within 3 months prior to screening and/or who are planning to receive such a vaccine during the study duration.
* History of any drug or alcohol abuse in the past 2 years
* Regular alcohol consumption in males \>21 units per week and in females \>14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
* Current smokers and those who have smoked within the last 12 months
* Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
* Confirmed positive drugs of abuse test result at screening or admission

Where it's running

• Quotient Sciences
  Nottingham, United Kingdom Recruiting

Study contacts

• Study coordinator: Josianne Nitcheu
• Email: josianne.nitcheu@abivax.com
• Phone: 33781759766

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?

  This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.

  Recruiting Applied Science & Performance Institute · Tampa, Florida · NCT07760506

• NVTIA Ergothioneine for Healthy Aging and Skin Health

  This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.

  Recruiting European Life Science Research Association · Dhaka · NCT07750002

• Miricell supplementation and markers of healthy aging

  This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.

  Recruiting Nutraland USA, Inc. · Canfield, Ohio · NCT07675200

• Does daily lean beef support brain health in older adults

  In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.

  Recruiting South Dakota State University · Brookings, South Dakota · NCT07623785

• Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment

  This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.

  Recruiting at 2 sites Universidad Antonio de Nebrija · Madrid, Madrid and 1 other locations · NCT07598409

• SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults

  A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.

  Recruiting Sheba Medical Center · Ramat Gan, Tel Aviv · NCT07596576

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.